About Alpha Biologics
Alpha Biologics is an independent contract biomanufacturing organization offering FDA/EMEA cGMP compliant services to the worldwide pharmaceutical and biotechnology industry. Initial process development is undertaken by Alpha's highly experienced team in Cambridge, England, before being transferred to the new 5,000 sq metre facility in Malaysia for final process technology transfer and manufacturing of biologics drugs for pre-clinical and clinical trials. The facility has been designed to produce primarily mammalian cell secreted proteins, including monoclonal antibodies and recombinant proteins. Future expansion will be in two stages - a 'fill/finish' operation and a microbial cell facility. Managed by a team of specialists with cGMP manufacturing experience in the US and Europe that will ensure the highest standards of production and regulatory compliance. In February 2011, Alpha Biologics was acquired by Viropro. The valuation of Alpha Biologics was $21 million.
Alpha Biologics Patents
Alpha Biologics has filed 5 patents.
Clusters of differentiation, EC 3.4.21, Transcription factors, HIV/AIDS, Immunology
Clusters of differentiation, EC 3.4.21, Transcription factors, HIV/AIDS, Immunology
Latest Alpha Biologics News
Sep 20, 2014
Alpha Biologics Assets Seized by Bank Pembangunan Malaysia SAN JOSE, Calif., Sept. 19, 2014 /PRNewswire/ -- Viropro, Inc. (OTCBB: VPRO) today announced that Bank Pembangunan Malaysia Berhad (BPMB) has seized the assets of Alpha Biologics Sdn Bhd (Alpha), a wholly owned subsidiary of Viropro located in Penang, Malaysia. The Bank has appointed Lim San Peen of PricewaterhouseCoopers Advisory Services Sdn Bhd as Receiver and Manager of the Alpha property pursuant to Section 188(1)(a) of the Companies Act 1965 (Malaysia) under the powers contained in the Debentures between Alpha and BPMB dated July 25, 2006 and December 22, 2009. The Receiver and Manager has advised the Directors of Alpha that their powers to deal with the Company's property or to manage its undertakings are suspended. On July 25, 2006, Alpha entered into a debenture agreement with BPMB for RM 20 million (US$6.2 million at current exchange rates.). On December 22, 2009, Alpha entered in a debenture agreement with BPMB for an additional RM 5 million. As of July 31, 2014, the outstanding balance on the loans plus accrued interest and penalties was approximately RM 22.1 million (US$6.8 million). Representatives from Viropro, acting on behalf of Alpha, had previously met with the members of the staff of the Credit Recovery Group at BPMB and presented a proposal for restructuring the Alpha debt. No reference was made to the Company's proposal in the notification regarding the appointment of the Receiver and Manager. "We are deeply disappointed and dismayed by this unexpected and counter-productive action by Bank Pembangunan," commented Bruce Cohen, Viropro Chairman. "Having presented a restructuring proposal in good faith, we were surprised by the lack of a response to our plan and the unexpected decision to appoint a Receiver and Manager without any notice. " Citing Sections 188(1)(b) and 189(2) of the aforementioned Companies Act, Mr. Lim ordered the Alpha Directors to turn over all of its assets and records to him within 14 days. Mr. Lim also ordered the Directors not to carry on Alpha's business in any way nor enter into any commitment on behalf of Alpha with his prior approval. "This action by the Bank undermines our ability to enter into negotiations with partners, restore the business of Alpha and house our new development programs in Malaysia," said Joseph Vallner, Viropro President and CEO. "At full capacity, the Alpha facility would have created as many as a hundred good paying jobs for highly skilled graduates of Malaysia's universities. " Construction of the Alpha facility was completed in 2010. In 2014, the facility was vandalized on several occasions, resulting in significant damage to the building's electrical system and a number of specialized instruments. Coincident with the delivery of the notice regarding the appointment, representatives from PricewaterhouseCoopers dismissed the security guards retained on behalf of Alpha and replaced them with guards of their own. Viropro also announced today that the Company is undertaking a comprehensive review of its strategy and operations to identify opportunities to enhance shareholder value and to determine the best course of action. About Viropro Viropro is engaged in the development and manufacturing of biopharmaceuticals. Viropro seeks to offer cost-effective and timely solutions to the biopharma industry from drug concept through to product manufacturing. About Bank Pembangunan Malaysia Berhad Bank Pembangunan Malaysia Berhad (BPMB) is wholly owned by the Malaysia Government through the Minister of Finance. BPMB is mandated to provide medium to long term financing for Islamic and conventional facilities to capital intensive industries, which include infrastructure projects, maritime, technology and oil & gas sectors.
Alpha Biologics Frequently Asked Questions (FAQ)
When was Alpha Biologics founded?
Alpha Biologics was founded in 2003.
What is Alpha Biologics's latest funding round?
Alpha Biologics's latest funding round is Acquired.
Who are the investors of Alpha Biologics?
Investors of Alpha Biologics include Viropro, Oxford Capital Partners and Asiaprise Pharma.
Who are Alpha Biologics's competitors?
Competitors of Alpha Biologics include Albireo Pharma, Bone Biologics, Abeome, Bloomage BioTech, ADV Bioscience, CMC Biologics, Irvine Pharmaceutical Services, Bioceros, Green Biologics, Althea Technologies and 30 more.
Compare Alpha Biologics to Competitors
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.
Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.
The company provide business development services to clients in the pharmaceutical, biotechnology, consumer health, and drug delivery industries worldwide. The company's team members represent an array of nationalities and a mix of commercial, manufacturing, medical, and scientific expertise, gained from decades of experience with both global pharmaceutical and development-stage companies
EnCor Biotechnology Inc. develops antibody reagents and enzyme-linked immunosorbent assays (ELISA) for academic, biopharmaceutical and clinical research.
AthenaES specializes in the development and commercialization of advanced biotechnology-based products. Throughout its eleven year history, the company has maintained a broad perspective for applying its core competency, the use of proteins and enzymes for commercial applications, to develop products. As such, the company currently markets its products and services through two business units and maintains an exploratory R&D group. The Athena Enzyme Systems Group aims to provide specialty reagents and proteins for the production and recovery of recombinant proteins along with providing contract R&D services. Products include: Expression Media, Serum-free Media, Protein Refolding kits, and the PDQ Protease Assay. This business unit also aims to provide specialized contract research, development and manufacturing services for the production of recombinant proteins. The Athena Environmental Services Group designs, develops and manufactures environmentally responsible products. Products developed include: The Bilge Pill, a biodegradable cleaning product for the removal of oil in boat bilges, and a plant nutrient supplement used in hydroponics, hobby gardens and horticulture that replaces conventional fertilizers, and the Sting Thing, an enzyme-based invertebrate sting treatment product. More recently, this group developed and has introduced a water-soluble, reversible glue, MagiGlue. The Athena Exploratory Science Group has the mission to pursue research with the potential for commercial, environmental and social impact. These projects are far reaching in their scope and represent high risk, high-value projects.
Therigy is a biopharmaceutical services company focused on improving the use of biotech therapy to achieve healthcare outcomes through the integration of therapy management and technology. Through Therigy's consulting and solutions delivery, clients can achieve optimal clinical results across all distribution channels. Therigy's customers include: health plans, pharmaceutical manufacturers, and pharmacy providers.